Characterization of circulating APOL1 protein complexes in African Americans

Allison Weckerle1+, James A. Snipes2+, Dongmei Cheng1, Abraham K. Gebre1, Julie A. Reisz1, Mariana Murea2, Gregory S. Shelness1, Gregory A. Hawkins3, Cristina M. Furdui1, Barry I. Freedman2, John S. Parks1*, Lijun Ma2*

Department of Internal Medicine, Sections on Molecular Medicine1 and Nephrology2, and Center for Genomics and Personalized Medicine Research3; Wake Forest School of Medicine, Winston-Salem, North Carolina 27157 USA

Running Title: Characterization of circulating APOL1

*These authors contributed equally to this work.

*Correspondence to:

John S. Parks, PhD
Wake Forest School of Medicine
Section on Molecular Medicine
Department of Internal Medicine
Medical Center Boulevard
Winston-Salem, North Carolina 27157-1053
Phone: (336) 716-2245
Fax: (336) 716
Email: jparkes@wakehealth.edu

Lijun Ma, MD, PhD
Wake Forest School of Medicine
Section on Nephrology
Department of Internal Medicine
Medical Center Boulevard
Winston-Salem, North Carolina 27157-1053
Phone: (336) 716-2209
Fax: (336) 716-4318
Email: lima@wakehealth.edu

Abbreviations

APOL1, apolipoprotein L1; CKD, chronic kidney disease; co-IP, co-immunoprecipitation; CVD, cardiovascular disease; FISH, fluorescence in situ hybridization; FPLC, fast protein liquid chromatography; FSGS, focal segmental glomerulosclerosis; HIVAN, HIV-associated nephropathy; HPR, haptoglobin-related protein; IEF, isoelectric focusing; MBP, maltose binding protein; NDGGE, non-denaturing gradient gel electrophoresis; NHAAN, Natural History of APOL1-Associated Nephropathy; TLF, trypanosome lytic factor
Abstract

Apolipoprotein L1 gene (APOL1) renal-risk variants are associated with nephropathy and cardiovascular disease (CVD) in African Americans; however, little is known about the circulating APOL1 variant proteins which reportedly bind to HDL. We examined whether APOL1 G1 and G2 renal-risk variant serum concentrations or lipoprotein distributions differed from non-risk G0 APOL1 in African Americans without nephropathy. Serum APOL1 protein concentrations were similar regardless of APOL1 genotype. In addition, serum APOL1 protein was bound to protein complexes in two non-overlapping peaks, herein referred to as APOL1 complex A (12.2 nm diameter) and complex B (20.0 nm diameter). Neither of these protein complexes associated with HDL or LDL. Proteomic analysis revealed that complex A was composed of APOA1, haptoglobin-related protein (HPR), and complement C3, whereas complex B contained APOA1, HPR, IgM, and fibronectin. Serum HPR was less abundant on complex B in individuals with G1 and G2 renal-risk variant genotypes, relative to G0 ($p=0.0002-0.002$). These circulating complexes may play roles in HDL metabolism and susceptibility to CVD.
Introduction

A major breakthrough in human molecular genetics was identification of the powerful contribution of apolipoprotein L1 gene (APOL1) G1 and G2 renal-risk variants to non-diabetic nephropathy susceptibility in African Americans (1). HIV-associated nephropathy (HIVAN), idiopathic focal segmental glomerulosclerosis (FSGS), severe lupus nephritis, sickle cell nephropathy, and hypertension-attributed nephropathy strongly associate with APOL1 G1 and G2 renal-risk variants on chromosome 22q13.1 (1-3). Although APOL1 mRNA and APOL1 protein are present in human kidney (4, 5), the major APOL1 reservoir appears to be circulating protein (5, 6). APOL1 was initially discovered as a minor apolipoprotein of plasma high density lipoproteins (HDL) (6); however, its distribution among HDL subfractions has not been well-defined. APOL1 nephropathy variants associate with HDL subfraction concentrations (7) and cardiovascular disease (CVD) risk, although controversial results have been reported with CVD (8-11). Trypanosome lytic factors (TLF1 and TLF2) contain APOL1 protein (12) and are minor HDL subfractions in humans that contribute to innate immunity via protection from infection, including from African trypanosomes (13).

Association was not observed between plasma APOL1 concentrations and APOL1 genotype in African Americans with treated HIV infection; plasma APOL1 levels also did not associate with the risk of HIVAN or chronic kidney disease (CKD) (14). Whether serum APOL1 protein levels and their distribution among HDL particles are associated with APOL1 genotypes in healthy individuals is unknown. Because free APOL1 protein may be taken up by podocytes in vitro (5), it remains critical to determine whether serum APOL1 concentrations or the structure/composition of variant APOL1 proteins and their associated complexes are specific to the G1 and G2 renal-risk variants, relative to non-risk G0.

To address these issues, serum APOL1 protein levels and size distribution were examined in age- and gender-matched African Americans without kidney disease based on APOL1 genotype using fast protein liquid chromatography (FPLC) and immunoblot analysis. Proteomics analysis was performed to compare the composition of APOL1 protein-containing complexes. These results provide novel
information on APOL1 genotype-specific circulating APOL1 protein and multiprotein complexes potentially involved in human CVD and HDL metabolism.
Materials and Methods

Study subjects

Eighty-four unrelated healthy African Americans without nephropathy (estimated glomerular filtration rate >60 ml/min/1.73 m$^2$ and urine albumin:creatinine ratio < 30 mg/g) were selected from Natural History of APOL1-Associated Nephropathy (NHAAN) participants. These participants had first degree relatives with non-diabetic etiologies of end-stage kidney disease. Among them (42 female/42 male), mean ± standard deviation (SD) age was 42.5 ± 13.8 years in females and 43.2 ± 13.4 years in males. Serum creatinine concentration (mean ± SD) was 0.79 ± 0.15 mg/dL in females and 1.05 ± 0.13 mg/dL in males. Seven men and seven women were included in each potential genotypic group, G0/G0, G1/G0, G2/G0, G1/G1, G2/G2, and G1/G2. Significant differences were not observed for age or kidney function with respect to APOL1 genotype. The Institutional Review Board at the Wake Forest School of Medicine approved the study and all participants provided written informed consent. Descriptive clinical data of the participants are provided in Table 1.

Measurement of serum APOL1 concentration

One microliter of sera from the 84 study participants was separated by 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA), and blocked for 1 hour at room temperature with Tris-buffered saline containing 1% skim milk powder, 0.1% Tween 20 (TBST). Blots were incubated overnight at 4°C with a monoclonal anti-APOL1 antibody (1:1,000, Epitomics, 3245-1). Membranes were washed three times in TBST and incubated for 1 hour in blocking buffer with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:20,000; Jackson Immuno-Research, West Grove, PA, USA). Bound antibodies were visualized using enhanced chemiluminescence (ECL; Super Signal West Pico; Thermo Pierce, Rockford, IL, USA) and recorded on X-ray film. Bands were scanned and densities quantitated using ImageJ software (http://rsbweb.nih.gov/ij/). As a standard, an APOL1-maltose binding protein (MBP) fusion protein previously generated in our lab (15) was loaded at varying concentrations.
**Fast protein liquid chromatography (FPLC)**

One hundred fifty microliters of sera from 4 healthy individuals homozygous for APOL1 G0, 4 homozygous for G1, and 4 homozygous for G2 variants were injected into a Superose 6 analytical column (GE Healthcare Life Sciences, Pittsburg, PA) for FPLC fractionation. Fractions 17-48 were collected at a flow rate of 0.4 mL/min. A total cholesterol (TC) enzymatic assay was performed to examine TC distribution among samples. Fractions 22-46 (sizes ranging from 7~20 nm or 66~1,240 kD, as determined by non-denaturing gradient gel electrophoresis) were analyzed by immunoblot, probed with APOL1, APOAI, and APOB antibodies, as described below.

**Non-denaturing gradient gel electrophoresis (NDGGE)**

One microliter of sera from 4 healthy individuals homozygous for APOL1 G0, 4 homozygous for G1, and 4 homozygous for G2 variants was electrophoresed in 4-20% native gels (BioRad Ready Gel® Tris-HCl gel) for 900 V/h and transferred to polyvinylidene fluoride (PVDF) membranes at 35 V for 22 h at 4°C. Membranes were blocked in 5% non-fat dry milk (NFDM)/0.1% TBST at room temperature for at least 1 hour. Anti-APOL1 (Epitomics, 1:1,000), anti-APOA1 (Meridian Life Science, 1:1,000), and anti-APOB (Academy Bio-Medical Co., 1:1,000) primary antibodies were incubated with membranes overnight at 4°C. Membranes were washed three times with 0.1% TBST, incubated with anti-rabbit (GE Healthcare, 1:15,000) or anti-goat (Santa Cruz Biotechnology, 1:6,000) HRP-conjugated secondary antibodies for 2 hours, and washed three times with 0.1% TBST. SuperSignal® West Pico Chemiluminescent substrate was added and membranes visualized using a FUJIFILM LAS-3000 imager.

**Density ultracentrifugation**

Twenty microliters of plasma from 4 healthy individuals homozygous for APOL1 G0, 4 homozygous for G1, and 4 homozygous for G2 variants were brought to a final volume of 1 mL with addition of normal saline and adjusted to \(d=1.225\) g/mL with solid KBr. Samples were overlaid with an additional 1 mL \(d=1.225\) g/mL KBr solution and ultracentrifuged in a TLA 120.2 rotor at 100,000 rpm for 4 hours at 15°C. Following ultracentrifugation, top (0.5 mL) and bottom (1.5 mL) fractions were collected.
Top (20 µL) and bottom (60 µL) fractions were then precipitated with trichloroacetic acid (TCA) and subjected to 12% SDS-PAGE followed by APOL1 and APOA1 immunoblot analysis, as described.

**Agarose gel electrophoresis**

One microliter of plasma was electrophoresed on 0.7% agarose gels at 100 mA for 2 hours. Gels were transferred to a PVDF membrane by pressure blotting for 2 hours. Following transfer, membranes were blocked with 5% NFDM/0.1% TBST for 1 hour at room temperature, and incubated with either rabbit anti-APOL1 (Sigma-Aldrich, 1:1,000) or goat anti-APOA1 (Meridian Life Science, 1:1,000) antibodies overnight at 4°C. Membranes were washed three times with 0.1% TBST, incubated with anti-rabbit (GE Healthcare, 1:15,000) or anti-goat (Santa Cruz Biotechnology, 1:6,000) HRP-conjugated secondary antibodies for 2 hours and washed three times with 0.1% TBST. SuperSignal® West Pico Chemiluminescent substrate was added and membranes visualized using a FUJIFILM LAS-3000 imager.

**Isoelectric focusing (IEF) electrophoresis**

Plasma (1.5 mL) from 4 healthy individuals homozygous for APOL1 G0, 4 homozygous for G1, and 4 homozygous for G2 variants was injected into a Superose 6 preparative column (GE Healthcare) for FPLC fractionation. Fractions were collected at a flow rate of 1 mL/min. A TC assay was performed to examine distributions among samples. Combined peak FPLC fractions for complex B (43-47) and complex A (58-62) were concentrated 10-fold with Amicon Ultra-4 MWCO 10 kD Centrifugal Filter Units (Millipore, Billerica, MA). Ten microliters of glycerol were added to 50 µL of concentrated FPLC APOL1 complex A and complex B samples, 15 µL of which were loaded onto a Criterion pH 3-10 IEF gel and electrophoresed at 100 V for 1 hour, 250 V for 1 hour, then 500 V for 30 min. The gel was transferred at 100 V for 1 hour in 0.7% acetic acid. The primary antibody (Epitomics anti-APOL1) was diluted 1:3,000 and the secondary antibody (Jackson Immuno-Research goat anti-rabbit IgG) was diluted 1:20,000 for immunoblot analysis.

**Co-immunoprecipitation (co-IP)**
An N-terminal APOL1 (1-199 aa)-MBP fusion protein was obtained, as previously reported (15) (5). cDNA corresponding to APOL1 (amino acid residues 13-130 of the APOL1 reference sequence) was generated by PCR and cloned into the pMAL-C5E vector (New England Biolabs) to generate a maltose binding protein-APOL1 fusion protein in *Escherichia coli*. Primer sequences used for PCR were: forward, 5’ AAG GTA CCG GAG GAA GCT GGA GCG AGG 3’; reverse, 5’ ACC GTCGAC TCA CCT TCT TAT GTT ATC TCT 3’. A polyclonal antibody against this fusion protein was raised in a rabbit (Lampire Biological Labs, Pipersville, PA). Lampire anti-APOL1 IgG was purified with a Melon Gel IgG Purification Kit (Thermo) according to the manufacturer’s instructions. Twenty microliters of complex A and 200 µL of complex B APOL1 peak fractions, determined by FPLC, were diluted to 1 mL with phosphate-buffered saline (PBS) in a 1.5 mL centrifuge tube. Rabbit anti-APOL1 antibody (50 µL; Lampire) was then added. The antibody-immunoprecipitate (IP) mixture was incubated overnight at 4°C by gentle mixing on a shaker. Sequential incubation at 4°C was applied for 1 hour after addition of 40 µL Protein A Agarose slurry (Invitrogen, Grand Island, NY). The tube was centrifuged again at 1,000-3,000 x g for 2 minutes at 4°C, supernatant removed, and the bead mixture washed three times using PBS. After washing, 20 µL 2X SDS-PAGE loading buffer was added to the bead-antibody mixture. The mixture was heated at 95°C for 5 minutes, beads were spun down, and supernatant kept for immunoblot analysis with mouse anti-APOL1 antibody (Novus), goat anti-APOA1, mouse anti-HPR (Abcam), and other antibodies against candidate partners of APOL1 complexes (antibody details in Supplementary Table 1)

**Proteomics analysis**

Concentrated complex A and B fractions (see *IEF electrophoresis* section above) were analyzed by NDGGE and IEF. Gels were stained with SYPRO® Ruby (Invitrogen) overnight. After de-staining, bands were excised from the gel and subjected to proteomics analysis. In-gel digestion was performed with standard reduction (dithiothreitol) and alkylation (iodoacetamide) followed by proteolysis using MS grade trypsin (Pierce) in 50 mM NH₄HCO₃ overnight at 37 °C. Peptides were extracted from the gel, concentrated, and analyzed on a Dionex UltiMate 3000 splitless nanoLC system coupled to a Thermo
Orbitrap Velos Pro high resolution mass spectrometer. LC solvents were as follows: buffers A (98% water, 2% MeCN, 0.1% formic acid) and B (80% MeCN, 20% water, 0.1% formic acid). Peptides were loaded onto a nano trap C18 column (Acclaim PepMap 100, 100 μm x 2 cm, 5 μm) with a flow of 5 μL/min of 100% buffer A for 5 min, then separated using an analytical nano C18 column (Acclaim PepMap RSLC C18, 75 μm x 15 cm, 2 μm) with a gradient of 2 to 85% B over 160 min and a flow rate of 300 nL/min. The columns were held at 35 °C. Following separation, peptides were introduced to the mass spectrometer via positive nanospray with the following settings: spray voltage 1.9 kV, capillary temperature 200 °C. The mass spectrometer was operated in data-dependent top 10 mode using Xcalibur 2.1 (Thermo). MS spectra were acquired over the range of 150-2000 m/z at a resolution of 60,000. Precursor ions were fragmented using collision-induced dissociation (normalized collision energy of 35%, activation time 10 ms) and fragment ions detected in the linear ion trap. Acquired raw data were processed and searched using Proteome Discoverer v 1.4 with the Mascot search engine and the SwissProt human proteomic database. Search parameters allowed for 2 missed trypsin cleavages, a precursor mass tolerance of 10 ppm, and fragment mass tolerance of 0.8 Da. N-Terminal acetylation, cysteine carbamidomethylation and methionine mono-oxidation were selected as variable modifications. Identities of proteins within the complex were filtered at a false discovery rate of 0.01.
Results

*Serum APOL1 concentrations in healthy African Americans*

Serum samples from 84 age- and sex-matched NHAAN participants who had first-degree relatives with non-diabetic kidney disease were analyzed by immunoblot to determine whether circulating APOL1 concentrations were associated with *APOL1* renal-risk variant genotypes in African Americans without kidney disease. Seven male and seven female NHAAN participants in each genotype group (G0/G0, G1/G0, G2/G0, G1/G2, G1/G1, and G2/G2) were analyzed. Consistent with previous reports (6), two bands were seen, reflecting the two APOL1 isoforms (39 kD and 42 kD) present in the circulation. Although APOL1 concentrations varied among individuals, effects were genotype-independent (Fig. 1). Regardless of *APOL1* genotype, mean serum APOL1 concentrations were ~15 µg/mL compared with an APOL1-maltose binding protein fusion protein standard of known concentration (Fig. 1). Mean serum APOL1 concentrations for each genotype are shown in Table 1.

*Distribution of APOL1 on lipoprotein subfractions*

To examine potential differences in size distribution among APOL1-containing particles, NDGGE fractionation and immunoblot were performed on serum samples from African Americans lacking nephropathy with different *APOL1* renal-risk variant genotypes. Based upon APOA1 and APOB immunodetection, the vast majority of APOL1-containing particles appeared to distribute between typical HDL and LDL sized particles, irrespective of genotype (Fig. 2). The predominant band was ~12 nm in diameter (500 kD molecular weight [MW]), with a smaller APOL1-containing particle band near the LDL migration position (20 nm diameter; 1000 kD MW). Little, if any, serum APOL1 protein was in the unbound region of the gel (<7.1 nm) where lipid-poor and lipid-free apolipoproteins typically migrate (16) (Fig. 2). These results suggest that serum APOL1 is distributed on particles other than typical sized serum HDL and LDL.

Serum samples were fractionated by FPLC, lipoprotein elution was monitored by measuring total cholesterol (TC), and individual fractions were analyzed by immunoblot to better define APOL1-
associated lipoprotein complexes. APOL1 primarily eluted in fractions between the LDL and HDL (fractions 31-38) and, to a lesser extent, co-eluted with large LDL particles (fractions 26-28) (Fig. 3A, B). Herein, we refer to these fractions as APOL1 complex A and complex B, respectively, corresponding to the 12 nm and 20 nm diameter APOL1-containing particles identified using NDGGE (Fig. 2).

**Fractionation of serum APOL1**

To determine whether APOL1-containing complexes were stably bound to HDL or LDL, density ultracentrifugation at d= 1.225 g/mL KBr was performed using sera from healthy African Americans with different APOL1 genotypes. Based on immunoblot analysis, > 90% of APOL1 protein was found in the d>1.225 gm/ml (bottom) fraction, whereas >90% of APOA1 was in the d<1.225 gm/ml (top) fraction, suggesting that APOL1 was not as strongly associated with HDL as APOA1 (Fig. 4A). This finding was independent of APOL1 genotype. Moreover, ultracentrifugation or presence of high salt (i.e., 1.225 gm/ml KBr) did not impact the FPLC elution position of APOL1, suggesting that APOL1 was in a large complex that did not contain sufficient lipid to allow floatation at d<1.225 gm/ml (Fig. 4B). Another method (agarose gel electrophoresis) was used that separates lipoproteins primarily by charge, rather than size, to determine whether APOL1 co-migrated with HDL. Serum APOL1 migrated in the beta/pre-beta position characteristic of lipid-free APOA1, LDL and VLDL, not in the alpha position where HDL particles migrate (Fig. 4C). This also suggests that serum APOL1 is not bound to HDL particles. Immunoblot analysis of d>1.225 gm/ml (bottom) serum fractions subsequently separated by NDGGE demonstrated that APOL1 in complex A and B exhibited similar size distributions as in serum that was not subjected to ultracentrifugation. Combined results using three different lipoprotein separation procedures that rely on size, density, and charge support the conclusion that APOL1 is likely a component of multiprotein complexes similar in size to large HDL and large LDL particles.

**Composition of APOL1-containing complexes**

To determine whether there was a difference in the size of these complexes in African Americans with different APOL1 genotypes, a two-step fractionation of sera was used involving FPLC followed by
NDGGE for serum samples (1.5 ml) from 6 individuals with different APOL1 genotypes (G0/G0, G1/G1, and G2/G2; N=2 per genotype). APOL1 immunoblot of NDGGE gels demonstrated that complex A (~12 nm diameter) was composed of three distinct size particles, defined as complexes A-α, A-β, and A-γ, whereas only a single band was apparent for complex B (~20 nm diameter) (Fig. 5A).

Concentrated complex A and complex B was separated by IEF based on isoelectric point (pI). Complex A separated into three bands with distinct pI values (assigned as A-1, A-2, and A-3 from top to bottom), and complex B remained as one band (Fig. 5B). Bands were carefully excised from gels for protein identification via mass spectrometry. The distinct size components of complex A (α, β, and γ) detected by NDGGE were consistent with A-1, A-2, and A-3 on the IEF gel, respectively. Hereafter, these complexes are referred to as A-α, -β and -γ, respectively.

Table 2 lists the candidate proteins that were identified by mass spectrometry from complex A and complex B (on both NDGGE and IEF gels) in 6 healthy African Americans. Immunoprecipitation of APOL1 complex A and complex B using a rabbit anti-APOL1 antibody directed at the N-terminus of APOL1 was performed using 12 additional serum samples from African Americans with different APOL1 genotypes (G0/G0, G1/G1, and G2/G2; N=4 per genotype). The anti-APOL1 immunoprecipitates were next examined by immunoblot analysis using antibodies targeting proteins that were identified by mass spectrometry. APOL1, HPR, and APOA1 appeared on both complex A and complex B; however, complement C3 was unique to APOL1 complex A (Fig. 6B). Fibronectin appeared as a unique polypeptide on APOL1 complex B (Fig. 6C), in addition to IgM (17). The other candidate polypeptides in Table 2 were not verified because their antibodies failed to distinguish the intensity of corresponding polypeptide signals via immunoblot between co-immunoprecipitation of APOL1 peak FPLC fractions with Lampire rabbit anti-APOL1 (N-terminus) IgG and that with the same amount of pre-bleed rabbit IgG; antibodies to candidate polypeptides on APOL1 complexes have been verified in human sera by immunoblot with clean bands of expected sizes.
APOL1 protein concentrations in complex A and complex B peak fractions were calculated in 12 unrelated African Americans with APOL1 G0/G0, G1/G1, and G2/G2 genotypes (N=4 per genotype) via immunoblot against a standard curve of known concentrations of MBP-APOL1 (N-terminal) fusion protein using methods previously described (5). When FPLC complex B peak fractions containing 10 ng of APOL1 were probed with HPR antibody for immunoblot analysis, HPR-α, a proteolytic fragment of HRP (see below), was less abundant on complex B in individuals with APOL1 G1/G1 and G2/G2 genotypes, relative to those with G0/G0 genotypes (Fig. 7A, B). However, no significant pattern for HPR-α was observed on complex A in individuals with different APOL1 genotypes.

The HPR-α distribution pattern was consistent with that of APOL1 following FPLC fractionation (Fig. 8A). HPR-α was present on APOL1-containing protein complexes, whereas HPR-α was absent in the supernatant following APOL1 co-immunoprecipitation (Fig. 8B). After normalization for APOL1 content, no other differences were observed in APOL1 genotype-dependent distributions with other components of APOL1 complexes.

Potential surface epitope conformational changes of APOL1 protein related to G1 and G2 variants

To detect potential surface epitope conformational differences between reference APOL1 (G0) and renal-risk (G1, G2) variants, the avidity of monoclonal APOL1 antibody (Epitomics) to APOL1 was tested on FPLC-isolated complex B from healthy African Americans with different APOL1 genotypes. Peak fractions from the aforementioned 12 individuals containing 10 ng APOL1 were separated by NDGGE. Immunoblot analysis was performed using an Epitomics APOL1 antibody targeting amino acids 300-330. Signal intensity was significantly higher in complex B peak fractions from those with APOL1 G1/G1 or G2/G2 variants relative to G0/G0 (Fig. 9). Potential differences among APOL1 genotypes were also examined in complex A; however, no significant differences were observed (data not shown).
Discussion

Differences between circulating APOL1 G0 and mutant G1 and G2 renal-risk variant proteins were analyzed in an attempt to better understand potential roles in human disease. APOL1 is predominantly present in the circulation and to a lesser extent in the liver and other solid organs, including the kidneys. Kidney APOL1 protein is enriched in glomerular podocytes, relative to proximal tubule and endothelial cells (5). Due to the abundance of APOL1 in human serum and uptake of free APOL1 into podocytes in vitro (5), it was initially hypothesized that circulating APOL1 protein might contribute to APOL1-associated nephropathy. Subsequent kidney transplantation studies failed to support this hypothesis (18-20); however, potential roles for circulating APOL1 protein in CVD and HDL-cholesterol metabolism remain plausible (7).

No association was observed between APOL1 G1 and G2 risk variant genotypes and serum APOL1 concentration by immunoblot in 84 African Americans lacking kidney disease. Individuals comprised all possible renal-risk variant genotype combinations (G0/G0, G1/G0, G2/G0, G1/G1, G2/G2, and G1/G2) with 14 healthy individuals of similar age and equal sex distributions in each group. We estimate presence of ~0.75 power to detect a one-fold difference in serum APOL1 protein in genotypic groups (versus G0/G0), assuming $\alpha=0.05$ (two-sided). Comparing subjects with two APOL1 renal-risk alleles versus zero or one, estimated power would reach ~0.80 for detecting 50% differences in serum APOL1. These results confirm the observations of Bruggeman et al. (14) in African Americans with HIV infection. As serum APOL1 protein concentrations are genotype-independent, it appears more likely that potential risk for disease may relate to protein function rather than quantity (14).

The size distribution of APOL1-containing particles in human sera, relative to HDL and LDL, was assessed using NDGGE. This fractionation procedure is less disruptive to HDL particle distribution than ultracentrifugation (21, 22). APOL1-containing particles were present in two major protein complexes: APOL1 complex A (12 nm diameter, 500 kD) and APOL1 complex B (20 nm diameter, 1000 kD); patterns were consistent with those seen on fractionation using FPLC. APOL1 complex A is larger
than typical HDL particles (8-12 nm), with similar distributions noted across APOL1 G0/G0, G1/G1, and G2/G2 genotypes. Following density ultracentrifugation of plasma adjusted to $d=1.225 \text{ g/mL KBr}$ (standard for plasma lipoprotein isolation) (23), more than 90% of APOL1 (G0, G1, and G2) failed to “float” with other apolipoproteins such as APOA1, surprising since it had been assumed that APOL1-containing particles were a stable component of HDL (6). Lipids were not directly measured in complex A or complex B; however, both are likely to be lipid-poor since they reside in the bottom fraction after density ultracentrifugation. TLF1 floated following density ultracentrifugation at a slightly higher density ($d=1.25$) in a report by Thomson et al. (17). That report did not examine APOL1; as such, the ratios of APOL1 in top and bottom fractions remain unknown. Additionally, agarose gel electrophoresis revealed that APOL1 does not migrate to the position of serum HDL particles, evidenced by its migration at the $\beta$/pre-$\beta$ position, compared with HDL that migrates at the $\alpha$ position. This is consistent with NDGGE data showing that APOL1 has a larger size distribution than APOA1 and suggesting that APOL1 is not associated with normal size HDL particles (Fig. 2). Based on the results from three fractionation procedures, APOL1-containing complexes do not appear to reside in ‘typical’ serum HDL particles as defined by density, charge and size. Previous studies have shown that a small percentage (~5%) of plasma HDL particles containing APOA1 are lipid-poor, smaller in size (<7 nm diameter) than most plasma HDL, and migrate in the pre-$\beta$ position on agarose gels. These so called “pre-$\beta$ HDL” are likely newly assembled nascent HDL particles generated by ATP binding cassette transporter A1 or products of plasma HDL remodeling by lipases or lipid transfer proteins (24-26). Another study used immunoaffinity chromatography to isolate lipid-poor (~3% lipid), phospholipid-transfer protein-APOA1 complexes containing proteins involved in innate immunity (27), suggesting that HDL should be more generically defined as APOA1-containing complexes/particles, particularly those lipid-poor APOA1 complexes involved in innate immunity.

Proteomic analyses were performed to detect potential differences in the composition of APOL1 complex A and complex B in healthy African Americans with APOL1 G0/G0, G1/G1, and G2/G2
genotypes. Following FPLC fractionation of sera, complex A and B were applied to IEF and NDGGE to further separate complexes by isoelectric point (pI) and particle size, respectively. This was an attempt to narrow the number of candidate proteins by prioritizing common polypeptide identities through different separation methods for subsequent proteomic analyses. Subsequent immunoblot and immunoprecipitation verification of results support the conclusion that circulating APOL1 complexes are likely to be the previously identified TLF1 and TLF2 based on complex size (13) and matching APOL1 and HPR-α FPLC elution profiles (Fig. 8A). Co-immunoprecipitation of APOL1 captured nearly all HPR-α (Fig. 8B), providing additional evidence that APOL1 and HPR-α co-exist in one serum protein complex. HPR is a core component of TLFs based on its ability to induce trypanosome lysis. HPR is synthesized as a 45-kD protein that is proteolytically cleaved to form an α- and β-chain, which remain connected via a disulfide bond (28). The HPR-α chain is a 13 kD N-terminal HPR fragment that retains its signal peptide (29, 30). Since haptoglobin (HP) and HPR are highly homologous, HPR/HP antibodies recognize both HPR and HP. The size differences between HPR-α (13 kD) and HP1-α (16 kD) or HP2-α (18 kD) is the only way to distinguish the probed polypeptide by the HPR antibody (28), which recognizes the N-terminus of HP/HPR. Therefore, the HPR-α here actually represents HPR. The trypanolytic activity profile (17) is consistent with our APOL1 distribution pattern following FPLC fractionation. The presence of APOA1 and HPR in complex A is consistent with that of TLF1 (29) and the presence of APOA1, HPR, and IgM is consistent with that of TLF2 (29). APOL1 complex A and B both contain APOL1, APOA1, and HPR. Novel components for both APOL1-containing complexes were identified (complement C3 in complex A or TLF1; and fibronectin in complex B or TLF2).

An APOL1 epitope conformational change is expected for the SRA interaction domain that surrounds the G1 and G2 renal-risk variants (31). However, the surface epitope exposure also appeared to be altered in the region between the membrane-addressing and SRA-interacting domains. Increased avidity to APOL1 antibody (Epitomics) for the G1/G2 variants was observed (Fig. 9). We speculate the increased APOL1 signal for complex B in individuals with G1 or G2 variant following NDGGE (Fig. 9).
could represent increased exposure of APOL1 amino acids 300-330 and/or lower binding of other protein(s) in that region on the surface of the protein complex; the lower signal of HPR-α on complex B in individuals with G1 or G2 variants (Fig. 7) may partially explain its increased avidity to Epitomics anti-APOL1 antibody, although the G1 and G2 variants are located beyond amino acid 340 (1).

Based on APOL1 co-immunoprecipitation experiments and serum APOL1/HPR distribution patterns following FPLC, serum APOL1 coexists with HPR. We could not determine whether serum APOL1 is exclusively complexed with HRP because existing HPR antibodies do not allow complete and specific immunoprecipitation of HRP. HPR and APOA1 are secreted from the liver and their mRNAs are absent in kidney. However, HPR and APOA1 proteins are present in kidney tubule cells. It appears likely that APOL1 protein in podocytes is predominantly locally synthesized (4, 5). A considerable amount of HDL APOA1 is catabolized in the kidney in human APOA1 transgenic mice and nonhuman primates (32, 33). APOL1 (5), APOA1, and HPR proteins are present in renal tubule cells but not glomeruli, whereas HPR and APOA1 mRNAs are absent in glomeruli (data not shown). It is possible that circulating APOL1 complexes/TLFs are catabolized by renal tubule cells (34), instead of being directly involved in glomerulosclerosis as we originally hypothesized. Although our results do not support a role for the APOL1 complexes in the pathogenesis of glomerulosclerosis due to the absence of APOA1 and HPR (mRNAs and proteins), the key components of APOL1 complexes (TLF1 and TLF2), in glomeruli, it clarifies the perspective that locally synthesized APOL1 in the kidney, especially in glomerular podocytes, is the major player of focal glomerulosclerosis.

We conclude that the majority of circulating APOL1 resides in lipid-poor multiprotein complexes, the contents of which largely represent TLFs, not typical lipid-enriched HDL particles. APOL1 G1 and G2 renal-risk variant genotypes appear to alter the composition, and potentially the conformation, of these multiprotein complexes. Potential roles for genotype-specific alterations in APOL1-protein complexes require further study in human disease, particularly vascular disease and susceptibility to development of calcified atherosclerotic plaque.
Acknowledgement

This project was supported by NIH R01 DK070941 (BIF) and R01 DK084149 (BIF).

Disclosure

All authors declare no competing interests.
References


_Am. J. Transplant._ **12**: 1924-1928.


Figure Legends

**Fig. 1. APOL1 serum concentration is variable and genotype-independent.** Representative immunoblot of serum samples from homozygous reference (G0/G0), homozygous G1 (G1/G1), homozygous G2 (G2/G2), heterozygous G1 (G1/G0), heterozygous G2 (G2/G0), and compound heterozygous (G1/G2) African Americans (n = 14/genotype) compared with an APOL1-maltose binding protein fusion protein standard of known concentrations (left).

**Fig. 2. Apolipoprotein distribution among serum lipoprotein subfractions.** One microliter of serum from homozygous APOL1 (G0, G1 and G2) individuals was fractionated on 4-20% non-denaturing gradient gels and subjected to immunoblot analysis for APOL1, APOB and APOA1. Average hydrodynamic diameter of standard proteins is shown on the left side of the blot and molecular weight range is shown on the right side along with the approximate size range for LDL and HDL.

**Fig. 3. APOL1 mainly elutes with particles similar in size to large HDL.** Human serum was size-fractionated by FPLC and eluted fractions were monitored for total cholesterol (TC; panel A) and apolipoprotein distribution (B). A) TC distribution for representative serum sample for homozygous APOL1 (G0, G1 and G2) individuals. B) Individual FPLC fractions were immunoblotted for APOB, APOL1 and APOA1. Two column regions enriched in APOL1 were identified; one containing most of the serum APOL1 (complex A; fractions 31-38) and a minor fraction (complex B; fractions 26-28).

**Fig. 4. APOL1 does not associate with HDL in human serum.** A) African American serum was subjected to density ultracentrifugation at \( d = 1.225 \) g/ml. Top (T) and bottom (B) fractions were then analyzed by immunoblot to visualize APOL1 and APOA1. Immunoblots of bottom fractions (B) indicate that most of the APOL1 in circulation does not associate with HDL, whereas APOA1 floats in the top fractions (T). + represents serum that did not undergo density ultracentrifugation. Results are representative of homozygous APOL1 (G0, G1 and G2) individuals. B) Following ultracentrifugation, bottom fractions were size-fractionated by FPLC. Complex A, complex B and the lipid-free fraction (fractions 45-48, Figure 3) were pooled and separated by non-denaturing gradient gel electrophoresis to determine the elution position of APOL1. Lanes 1-3: serum was adjusted to \( d = 1.225 \) g/ml prior to FPLC fractionation. Lane 1, starting serum; Lanes 2 and 3, complex A and lipid-free fraction, respectively, from FPLC fractionation. Results demonstrate that complex A was not disrupted by 1.225 g/ml KBr. Lanes 4-6: bottom fraction (\( d > 1.225 \) g/ml) from ultracentrifugation of serum was size-fractionated by FPLC. Lane 4, unfractionated bottom fraction; Lanes 5 and 6, complex A and lipid-free fraction, respectively, from FPLC fractionation of bottom fraction. Lanes 7-9: bottom fraction (\( d > 1.225 \) g/ml) from ultracentrifugation of serum was size-fractionated by FPLC. Lane 7, unfractionated bottom fraction; Lanes 8 and 9, complex B and lipid-free fraction, respectively, from FPLC fractionation of bottom fraction. C) One microliter of human serum from African Americans homozygous for APOL1 (G0 and G1) was electrophoresed in 0.7% agarose and immunoblotted for APOA1 and APOL1 to
examine apolipoprotein migration in agarose gels. APOL1 does not co-migrate with α particles, which correspond to HDL. APOA1, the major protein of HDL, migrates at the α position.

**Fig. 5. Determining the composition of APOL1-containing complexes.** Five FPLC fractions surrounding APOL1 complex A and complex B were pooled and concentrated. Samples were loaded onto A) 4-20% non-denaturing gradient gels or B) IEF gels, followed by immunoblot analysis.

**Fig. 6. Confirmation of APOL1-associated protein components.** A) Co-immunoprecipitation (co-IP) of APOL1 with protein components in whole serum using the N-terminal rabbit anti-APOL1 antibody (APOL1) and pre-bleed normal IgG (Pre-bleed). APOL1, APOA1 and HPR are confirmed to be present in co-immunoprecipitated APOL1 complexes. B) Co-IP of APOL1 in complex A FPLC peak fractions. APOA1, HPR and complement C3 are confirmed to be present in co-immunoprecipitated APOL1 complex A. C) Co-IP of APOL1 in complex B FPLC peak fractions. Fibronectin, APOA1 and HPR are confirmed to be present in co-immunoprecipitated APOL1 complex. L1, anti-APOL1 antibody (Lampire); P, pre-bleed normal IgG from the same rabbit.

**Fig. 7. HPR-α is less abundant on complex B in APOL1 G1/G1 and G2/G2 individuals relative to G0/G0.** A) APOL1 complex B peak fractions from AA individuals with different APOL1 genotypes (G1/G1, G2/G2 and G0/G0) were first quantified for APOL1 concentration by denatured immunoblot using Epitomics anti-APOL1 antibody and comparison with a series of APOL1 fusion proteins with known concentrations (see Figure 1). Each well contains 10 ng APOL1. Samples were subjected to 4-20% SDS-PAGE and immunoblotting using specific antibody to APOL1 (Lampire anti-APOL1 polyclonal antibody) and HPR. The signal intensity of APOL1 was similar among complex B samples of different APOL1 genotypes. However, the relative amount of HPR-α residing on APOL1 complex B appeared to be less abundant for homozygous G1 carriers.

**Fig. 8. HPR-α distribution is consistent with that of APOL1 following FPLC.** A) FPLC fractions were subjected to 4-20% SDS-PAGE and probed with APOB, APOA1, APOL1, and HPR antibodies via immunoblot analysis. APOA1 and APOB100 peak fractions represent the enrichment of HDL and LDL, respectively. The peak fractions for APOL1 and HPR-α are consistent, indicating the positions of complex A and B. B) APOL1 complex A peak fractions from G1/G1, G2/G2 and G0/G0 individuals and one sample of peak APOL1 complex B from a G0/G0 subject were co-immunoprecipitated with rabbit anti-N terminal APOL1 antibody (APOL1) or pre-bleed IgG from the same rabbit (Pre-bleed). APOL1 and HPR-α only appeared in co-immunoprecipitated APOL1, but not in the supernatant (Flow-through), indicating the co-existence of APOL1 and HPR in serum complexes A and B. The absence of APOL1 and HPR in the APOL1 supernatant suggests that anti-APOL1 IgG was sufficient to precipitate all APOL1 in the sample. The absence of APOL1, APOA1 and HPR in the pre-bleed rabbit IgG co-IP indicates the specificity of the antibodies. Since APOB is enriched in complex B fractions and APOB also appeared in the pre-bleed rabbit co-IP, it is undetermined whether APOB is specifically present on complex B.

**Fig. 9.** Estimate of potential surface epitope conformational change of APOL1 protein caused by G1 and G2 variants. APOL1 complex B peak fractions containing 10 ng of APOL1 (quantified by Epitomics anti-APOL1 antibody shown in Fig. 7) were run on a 4-20% non-denaturing gradient gel at 150 V for 1 h at room temperature, transferred to a cellulose membrane, and probed with the same Epitomics anti-APOL1
antibody (immunogen within aa 300-330) via immunoblot. APOL1 signal intensity was significantly higher for complex B in G1/G1 and G2/G2 individuals compared to G0/G0.
Table 1. Serum APOL1 levels and other clinical data by APOL1 genotype in 84 AA subjects without kidney disease.

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>G0/G0</th>
<th>G1/G0</th>
<th>G2/G0</th>
<th>G1/G2</th>
<th>G1/G1</th>
<th>G2/G2</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N(M/F)</td>
<td>84(41/41)</td>
<td>14(7/7)</td>
<td>14(7/7)</td>
<td>14(7/7)</td>
<td>14(7/7)</td>
<td>14(7/7)</td>
<td>14(7/7)</td>
<td>1.000</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>42.8 ± 13.5</td>
<td>42.5 ± 12.5</td>
<td>42.0 ± 13.6</td>
<td>43.5 ± 13.4</td>
<td>42.6 ± 14.0</td>
<td>42.3 ± 14.2</td>
<td>44.1 ± 15.7</td>
<td>0.999</td>
</tr>
<tr>
<td>African ancestry (%)</td>
<td>0.795 ± 0.089</td>
<td>0.773 ± 0.069</td>
<td>0.787 ± 0.119</td>
<td>0.795 ± 0.067</td>
<td>0.816 ± 0.096</td>
<td>0.796 ± 0.071</td>
<td>0.805 ± 0.108</td>
<td>0.864</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.920 ± 0.192</td>
<td>0.934 ± 0.207</td>
<td>0.900 ± 0.254</td>
<td>0.861 ± 0.183</td>
<td>0.923 ± 0.133</td>
<td>0.988 ± 0.094</td>
<td>0.912 ± 0.200</td>
<td>0.256</td>
</tr>
<tr>
<td>Cystatin C (mg/L)</td>
<td>0.709 ± 0.124</td>
<td>0.666 ± 0.131</td>
<td>0.711 ± 0.110</td>
<td>0.689 ± 0.118</td>
<td>0.679 ± 0.129</td>
<td>0.803 ± 0.073</td>
<td>0.707 ± 0.090</td>
<td>0.060</td>
</tr>
<tr>
<td>Urine Alb:Creat (mg/g)</td>
<td>6.30 ± 5.71</td>
<td>4.66 ± 4.47</td>
<td>5.04 ± 5.27</td>
<td>6.11 ± 5.18</td>
<td>6.44 ± 4.01</td>
<td>8.59 ± 7.16</td>
<td>6.96 ± 7.04</td>
<td>0.344</td>
</tr>
<tr>
<td>APOL1 (μg/ml)</td>
<td>20.5 ± 30.8</td>
<td>16.2 ± 13.0</td>
<td>25.0 ± 24.9</td>
<td>15.6 ± 22.1</td>
<td>17.7 ± 11.9</td>
<td>32.6 ± 62.4</td>
<td>15.8 ± 15.5</td>
<td>0.723</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>99.4 ± 54.5</td>
<td>101.3 ± 77.0</td>
<td>93.8 ± 50.0</td>
<td>110.6 ± 66.2</td>
<td>86.0 ± 34.1</td>
<td>103.6 ± 53.9</td>
<td>100.9 ± 39.4</td>
<td>0.881</td>
</tr>
<tr>
<td>TCHOL (mg/dl)</td>
<td>183.1 ± 36.5</td>
<td>179.5 ± 49.5</td>
<td>185.8 ± 35.0</td>
<td>186.8 ± 36.5</td>
<td>182.1 ± 29.9</td>
<td>175.6 ± 23.7</td>
<td>189.3 ± 43.5</td>
<td>0.945</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>50.7 ± 11.1</td>
<td>46.9 ± 10.5</td>
<td>52.7 ± 13.1</td>
<td>53.0 ± 10.8</td>
<td>51.1 ± 9.19</td>
<td>52.5 ± 11.0</td>
<td>48.0 ± 11.2</td>
<td>0.532</td>
</tr>
<tr>
<td>LDL (mg/dl)</td>
<td>111.5 ± 32.1</td>
<td>111.4 ± 41.7</td>
<td>115.7 ± 34.8</td>
<td>109.2 ± 30.5</td>
<td>110.4 ± 22.6</td>
<td>102.3 ± 25.8</td>
<td>120.2 ± 37.0</td>
<td>0.864</td>
</tr>
<tr>
<td>VLDL (mg/dl)</td>
<td>19.9 ± 10.8</td>
<td>20.3 ± 15.4</td>
<td>18.7 ± 9.91</td>
<td>22.2 ± 13.2</td>
<td>17.3 ± 6.80</td>
<td>20.7 ± 11.0</td>
<td>20.1 ± 7.80</td>
<td>0.875</td>
</tr>
</tbody>
</table>

P values were determined by ANOVA and indicate the difference across APOL1 genotype. P values were calculated for log transformed serum creatinine, cystatin C, APOL1, triglycerides, total cholesterol (TCHOL), HDL, LDL, VLDL, and urine albumin/creatinine ratio (Urine Alb:Creat) due to the skewness of raw data from normal distribution. The P value for serum creatinine level by APOL1 genotype was additionally adjusted for gender. Data are presented as the mean ± standard deviation.
Table 2. Identification of candidate polypeptides on APOL1 complex A and B by proteomics analysis.

<table>
<thead>
<tr>
<th>Candidate Protein</th>
<th>Accession No.</th>
<th>Molecular weight (kD)</th>
<th>Complex A</th>
<th>TLF1-α</th>
<th>TLF1-β</th>
<th>TLF1-γ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complement C3*</td>
<td>sp</td>
<td>P01024</td>
<td>CO3_HUMAN</td>
<td>187</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Haptoglobin-related protein*</td>
<td>sp</td>
<td>P00739</td>
<td>HPRT_HUMAN</td>
<td>39</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Haptoglobin</td>
<td>sp</td>
<td>P00738</td>
<td>HPT_HUMAN</td>
<td>45</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Alpha-2-macroglobulin</td>
<td>sp</td>
<td>P01023</td>
<td>A2MG_HUMAN</td>
<td>163</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Apolipoprotein A1*</td>
<td>sp</td>
<td>P02647</td>
<td>APOA1_HUMAN</td>
<td>31</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Apolipoprotein L1</strong>*</td>
<td>sp</td>
<td>O14791</td>
<td>APOL1_HUMAN</td>
<td>44</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Prothrombin</td>
<td>sp</td>
<td>P00734</td>
<td>THRB_HUMAN</td>
<td>70</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Complement C5</td>
<td>sp</td>
<td>P01031</td>
<td>CO5_HUMAN</td>
<td>188</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Complement C1r subcomponent</td>
<td>sp</td>
<td>P00736</td>
<td>C1R_HUMAN</td>
<td>80</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Apolipoprotein E</td>
<td>sp</td>
<td>P02649</td>
<td>APOE_HUMAN</td>
<td>36</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Clusterin</td>
<td>sp</td>
<td>P10909</td>
<td>CLUS_HUMAN</td>
<td>52</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Complement factor H</td>
<td>sp</td>
<td>P08603</td>
<td>CFAH_HUMAN</td>
<td>139</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Complex B</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ig mu chain C region*</td>
<td>sp</td>
<td>P01871</td>
<td>IGHM_HUMAN</td>
<td>49</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Fibronectin *</td>
<td>sp</td>
<td>P02751</td>
<td>FINC_HUMAN</td>
<td>263</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Alpha-2-macroglobulin</td>
<td>sp</td>
<td>P01023</td>
<td>A2MG_HUMAN</td>
<td>163</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Haptoglobin</td>
<td>sp</td>
<td>P00738</td>
<td>HPT_HUMAN</td>
<td>45</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Thrombospondin-1</td>
<td>sp</td>
<td>P07996</td>
<td>TSP1_HUMAN</td>
<td>129</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Apolipoprotein A1*</td>
<td>sp</td>
<td>P02647</td>
<td>APOA1_HUMAN</td>
<td>31</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Protein Name</td>
<td>Accession</td>
<td>Mw (kDa)</td>
<td>Present</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>------------</td>
<td>----------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haptoglobin-related protein*</td>
<td>sp</td>
<td>P00739</td>
<td>/HPTR_HUMAN</td>
<td>39</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Vitamin K-dependent protein S</td>
<td>sp</td>
<td>P07225</td>
<td>/PROS_HUMAN</td>
<td>75</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Apolipoprotein E</td>
<td>sp</td>
<td>P02649</td>
<td>/APOE_HUMAN</td>
<td>36</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td><strong>Apolipoprotein L1</strong>*</td>
<td>sp</td>
<td>O14791</td>
<td>/APOL1_HUMAN</td>
<td>44</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

Checkmarked proteins are present in both IEF and native gel APOL1-positive bands for pooled complex A and B from FPLC peak fractions.

*Indicates those candidate proteins that were confirmed via subsequent co-immunoprecipitation analysis.
Fig. 2

- **APOB**
  - G0/G0
  - G1/G1
  - G2/G2

- **APOAI**
  - G0/G0
  - G1/G1
  - G2/G2

- **LDL**
  - 1236 KD
  - 1048 KD

- **HDL**
  - 242 KD
  - 146 KD

- **66 KD**

- **7.1 nm**
- **8.2 nm**
- **12.2 nm**
- **17 nm**
- **20 nm**
Fig. 3
Fig. 4

A

<table>
<thead>
<tr>
<th></th>
<th>G0/G0</th>
<th>G1/G1</th>
<th>G2/G2</th>
<th>G0/G0</th>
<th>G1/G1</th>
<th>G2/G2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+</td>
<td>T</td>
<td>B</td>
<td>+</td>
<td>T</td>
<td>R</td>
</tr>
</tbody>
</table>

APOL1

APOA1

B

<table>
<thead>
<tr>
<th></th>
<th>Complex A</th>
<th>Complex B</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>8</td>
<td>9</td>
</tr>
</tbody>
</table>

C

APOA1

APOL1

β

α
Fig. 5
Fig. 6
Fig. 7
Fig. 8
<table>
<thead>
<tr>
<th></th>
<th>G1/G1</th>
<th>G2/G2</th>
<th>G0/G0</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Relative Signal Intensity</strong></td>
<td><img src="image_url" alt="Graph" /></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><img src="image_url" alt="Histogram" /></td>
<td><img src="image_url" alt="Histogram" /></td>
<td><img src="image_url" alt="Histogram" /></td>
</tr>
<tr>
<td><em>p</em></td>
<td>0.015</td>
<td>0.029</td>
<td></td>
</tr>
</tbody>
</table>